Mostrar el registro sencillo del ítem

dc.contributor.advisorMantilla García, Daniel Eduardo
dc.contributor.advisorOchoa Vera, Miguel Enrique
dc.contributor.authorRueda Badillo, Edward Yesid
dc.coverage.spatialFloridablanca (Santander, Colombia)spa
dc.coverage.temporal2013-2022spa
dc.date.accessioned2022-03-25T19:13:50Z
dc.date.available2022-03-25T19:13:50Z
dc.date.issued2022
dc.identifier.urihttp://hdl.handle.net/20.500.12749/16058
dc.description.abstractObjetivo: Evaluar la eficacia y seguridad del tratamiento con quimioterapia intraarterial a través de la arteria oftálmica en pacientes con retinoblastoma en FOSCAL- FOSCAL INTERNACIONAL en el periodo 2013-2020. Justificación: La quimioterapia intraarterial cambió la estrategia de tratamiento para el retinoblastoma, proporciona una alta tasa de éxito para salvar el globo ocular y controlar el tumor. Con el fin de ampliar el conocimiento sobre la factibilidad de este sofisticado procedimiento en un país de ingresos medios como el nuestro, queremos presentar nuestra experiencia en pacientes del noreste de Colombia con retinoblastoma intraocular manejados con quimioterapia intraarterial supraselectiva. Tipo de estudio: Se trata de un estudio descriptivo de cohortes basado en datos secundarios. Población: Se incluirán todos los pacientes elegibles con diagnóstico de retinoblastoma desde el 1 de enero de 2013 hasta el 1 de septiembre de 2020 sometidos a quimioterapia intraarterial selectiva a través de la arteria oftálmica en FOSCAL- FOSCAL INTERNACIONAL, será un estudio censal. Resultados: Al evaluar el total de ojos de los 10 niños afectados por retinoblastoma fue del 65% (13/20 ojos), de los cuales 11 fueron tratados con quimioembolización. Se realizó la categorización de estadios según la clasificación internacional de retinoblastoma, observándose que de los 11 ojos llevados al QIA, el 63,64% (n=7) eran categoría D, seguido de la categoría E 27,27% (n=3) y la categoría C 9,09% (n=1). Al evaluar la supervivencia global, ningún paciente falleció y la mediana de seguimiento fue de 53 meses. La supervivencia media libre de enucleación fue de 23 meses, la primera enucleación de los 11 ojos después de la quimioembolización fue a los 6 meses. Conclusiones: La quimioterapia intraarterial es una modalidad potente, segura y eficaz que puede reducir la tasa de enucleación en pacientes con retinoblastoma. Se observó mejor respuesta en el grupo C; sin embargo, sería ideal definir el riesgo/beneficio de dicho tratamiento para un mayor número de pacientes en etapas tempranas. Todos los pacientes del grupo E acabaron en enucleación, lo que refuerza los hallazgos de los diferentes estudios en los que la eficacia en estadios avanzados es baja y se prefiere la enucleación.spa
dc.description.tableofcontents1. INTRODUCCIÓN ................................................................................................... 10 2. DESCRIPCIÓN DEL PROBLEMA ...................................................................... 11 2.1 PLANTEAMIENTO DEL PROBLEMA ..................................................................................... 11 2.2 JUSTIFICACIÓN .................................................................................................................. 12 3.1 GENERALIDADES................................................................................................................ 13 3.2 EPIDEMIOLOGÍA ................................................................................................................ 13 3.3 ETIOLOGÍA ......................................................................................................................... 15 3.4 PATOGENÍA ....................................................................................................................... 16 3.5 PATRÓN DE CRECIMIENTO ................................................................................................ 17 3.6 DIAGNÓSTICO.................................................................................................................... 18 3.7 CLASIFICACIÓN .................................................................................................................. 23 3.8 ANATOMÍA DE LA ARTERIA OFTÁLMICA ............................................................................ 24 Variantes anatómicas:............................................................................................................. 26 Curso de la arteria oftálmica: .................................................................................................. 28 Ramas de la arteria oftálmica: ................................................................................................ 29 3.9 TRATAMIENTO .................................................................................................................. 31 3.9.1 Quimioterapia intraarterial (QIA) ................................................................................... 33 3.9.1.1 Indicaciones:................................................................................................................ 34 3.9.1.2 Contraindicaciones: ..................................................................................................... 35 3.9.1.4 Técnica: .................................................................................................................... 37 3.9.1.5 Complicaciones: .......................................................................................................... 41 Efectos secundarios sistémicos ............................................................................................... 42 Efectos adversos oculares ....................................................................................................... 42 Resultado visual ...................................................................................................................... 43 4. ESTADO DEL ARTE. ............................................................................................... 45 5. OBJETIVOS .............................................................................................................. 47 6. METODOLOGÍA ....................................................................................................... 48 7. ALMACENAMIENTO ELECTRÓNICO DE LA INFORMACIÓN ......................... 52 8. CONSIDERACIONES ÉTICAS ............................................................................... 54 CRONOGRAMA DE ACTIVIDADES .......................................................................... 55 9. RESULTADOS.......................................................................................................... 56 9.1 CARACTERIZACIÓN GENERAL DE LA POBLACIÓN ESTUDIADA ..................... 56 9.2 ANALISIS BIVARIADO ................................................................................................. 60 10. DISCUSIÓN............................................................................................................. 64 11. CONCLUSIONES ................................................................................................... 68 12. FORTALEZAS Y LIMITACIONES ........................................................................ 69 13. FINANCIACIÓN Y CONFLICTOS DE INTERÉS ................................................ 70 14. BIBLIOGRAFIA ...................................................................................................... 71spa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.titleQuimioterapia intra-arterial para el tratamiento del retinoblastoma: Experiencia de 8 años (2013 – 2020) en Clínica Foscal – Foscal Internacionalspa
dc.title.translatedIntra-arterial chemotherapy for the treatment of retinoblastoma: 8-year experience (2013 – 2020) at Clínica Foscal – Foscal Internacionalspa
dc.degree.nameEspecialistas en Radiología e Imágenes Diagnósticasspa
dc.publisher.grantorUniversidad Autónoma de Bucaramanga UNABspa
dc.rights.localAbierto (Texto Completo)spa
dc.publisher.facultyFacultad Ciencias de la Saludspa
dc.publisher.programEspecialización en Radiología e Imágenes Diagnósticasspa
dc.description.degreelevelEspecializaciónspa
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.localTesisspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdcc
dc.subject.keywordsMedical sciencesspa
dc.subject.keywordsHealth sciencesspa
dc.subject.keywordsRadiologyspa
dc.subject.keywordsDiagnostic imagingspa
dc.subject.keywordsIntra-arterial chemotherapyspa
dc.subject.keywordsOphthalmic arteryspa
dc.subject.keywordsPharmacologyspa
dc.subject.keywordsEye neoplasmsspa
dc.subject.keywordsEye diseasesspa
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga - UNABspa
dc.identifier.reponamereponame:Repositorio Institucional UNABspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.relation.references1. Suzuki S, Yamane T, Mohri M, Kaneko A. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011;118(10):2081-spa
dc.relation.references2. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008;115(8):13981404.e1spa
dc.relation.references3. Chawla B.(2020) Retinoblastoma: Diagnosis, Classification and Management. In: Khetan V. (eds) Intraocular Tumors. Springer, Singaporespa
dc.relation.references4. Li B., Zhang X. (2020) A Review of Retinoblastoma from the Perspective of Integrative Medicine. In: Wang N. (eds) Integrative Ophthalmology. Advances in Visual Science and Eye Diseases, vol 3. Springer, Singaporespa
dc.relation.references5. Abramson DH. Retinoblastoma in the 20th century: past success and future challenges the Weisenfeld lecture. Invest Ophthalmol Vis Sci. 2005;46(8):2683-2691spa
dc.relation.references6. Enrique MachíRetinoblastoma: a molecular, clinical and therapeutic approach. Archivos Venezolanos de Farmacología y Terapéutica, vol. 36, núm. 5, 2017, pp. 115-131spa
dc.relation.references7. Qian J. Some problems should be paid attention to in the treatment of retinoblastoma. Ophthalmology. 2009;18(6):367–9spa
dc.relation.references8. Wippold FJ, 2nd, Perry A. Neuropathology for the neuroradiologist: rosettes and pseudorosettes. AJNR Am J Neuroradiol. 2006;27(3):488–492.spa
dc.relation.references9. Mendoza PR, Specht CS, Hubbard GB, Wells JR, Lynn MJ, Zhang Q, Kong J, Grossniklaus HE. Histopathologic grading of anaplasia in retinoblastoma. Am J Ophthalmol. 2015;159(4):764–776spa
dc.relation.references10. Finger PT. The 7th Edition AJCC Staging System for Eye Cancer an international language for ophthalmic oncology. Arch Pathol Lab Med. 2009;133(8):1197–1198spa
dc.relation.references11. Gallie BL, Mallipatna A, Finger P, Zhao J, Kivela T, Chantada G, Lau W, Ramirez-Ortiz MA, Catala J, Yousef Y, Ushakova T, Yarovoy A, Wilson M, Khetan V, Walsh J, Blair P, Renner L, Teekappanava N. International survey of staging for retinoblastoma provides evidence for the 2016 8th Edition AJCC TNMH retinoblastoma cancer staging. Pediatr Blood Cancer. 2016;63:S21– S21spa
dc.relation.references12. Mallipatna AC, Gallie BL, Chevez-Barrios P, Lumbroso-Le Rouic L, Chantada GL, Brisse HJ, Doz F, Munier FL, Albert DM, Català-Mora J, Desjardins LG, Suzuki S, Carroll WL, Coupland SE, Finger PT. Retinoblastoma. In: Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC Cancer Staging Manual. 8. New York: Springer International Publishing; 2017spa
dc.relation.references13. Bin Li and Xiao Zhang A Review of Retinoblastoma from the Perspective of Integrative Medicinespa
dc.relation.references14. Chawla B., Seth R., Moksha L. (2016) Chemotherapy for Ocular Cancers. In: Velpandian T. (eds) Pharmacology of Ocular Therapeutics. Adis, Chamspa
dc.relation.references15. Rao R, Honavar SG. Retinoblastoma. Indian Journal of Pediatrics. 2017 Dec;84(12):937-944spa
dc.relation.references16. Novotný A, Krásný J. K diagnostice retinoblastomu ultrazvukem [Diagnosis of retinoblastoma using ultrasound]. Cas Lek Cesk. 1990;129(12):364-365.spa
dc.relation.references17. Moulin AP, Gaillard MC, Balmer A, Munier FL. Ultrasound biomicroscopy evaluation of anterior extension in retinoblastoma: a clinicopathological study. Br J Ophthalmol. 2012;96(3):337-340spa
dc.relation.references18. Vasquez LM, Giuliari GP, Halliday W, Pavlin CJ, Gallie BL, Héon E. Ultrasound biomicroscopy in the management of retinoblastoma. Eye (Lond). 2011;25(2):141-147spa
dc.relation.references19. Rootman DB, Gonzalez E, Mallipatna A, Vandenhoven C, Hampton L, Dimaras H, et al. Hand-held high-resolution spectral domain optical coherence tomography in retinoblastoma: clinical and morphologic considerations. Br J Ophthalmol. 2013;97:59–65spa
dc.relation.references20. Chawla B, Sharma S, Sen S, Azad R, Bajaj MS, Kashyap S, etal. Correlation between clinical features, MRI and histopathologic ‑ndings in retinoblastoma: a prospective study. Ophthalmology. 2012;119:850–6.spa
dc.relation.references21. de Jong MC, de Graaf P, Noij DP, Göricke S, Maeder P, Galluzzi P, etal. Diagnostic performance of magnetic resonance imaging and computed tomography for advanced retinoblastoma: a systematic review and metaanalysis. Ophthalmology. 2014;121:1109–18spa
dc.relation.references22. Razek AA, Elkhamary S. MRI of retinoblastoma. Br J Radiol. 2011;84(1005):775–784spa
dc.relation.references23. Galluzzi P, Hadjistilianou T, Cerase A, De Francesco S, Toti P, Venturi C. Is CT still useful in the study protocol of retinoblastoma? AJNR Am J Neuroradiol. 2009;30(9):1760–1765spa
dc.relation.references24. Chawla B, Duraipandi K, Sharma S.MRI in retinoblastoma associated orbital cellulitis. Ophthalmology. 2013;120:1308–9spa
dc.relation.references25. Reese AB, Ellsworth RM. The evaluation and current concept of retinoblastoma therapy. Trans Am Acad Ophthalmol Otolaryngol. 1963;67:164–72spa
dc.relation.references26. Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin N Am. 2005;18:41–53spa
dc.relation.references27. Shields CL, Mashayekhi A, Au AK, Czyz C, Leahey A, Meadows AT, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113:2276–80spa
dc.relation.references28. Michalinos A, Zogana S, Kotsiomitis E, Mazarakis A, Troupis T. Anatomy of the Ophthalmic Artery: A Review concerning Its Modern Surgical and Clinical Applications. Anat Res Int. 2015;2015:591spa
dc.relation.references29. Perrini P, Cardia A, Fraser K, Lanzino G. A microsurgical study of the anatomy and course of the ophthalmic artery and its possibly dangerous anastomoses. J Neurosurg. 2007;106(1):142-150spa
dc.relation.references30. Picard L., Vignaud J., Lombardi G., Roland J. Radiological anatomy of the origin of the ophthalmic artery. Modern Problems in Ophthalmology. 1975;14:164–169spa
dc.relation.references31. Hassler W., Zentner J., Voigt K. Abnormal origin of the ophthalmic artery from the anterior cerebral artery: neuroradiological and intraoperative findings. Neuroradiology. 1989;31(1):85–87spa
dc.relation.references32. Islak C., Ogüt G., Numan F., Cokyuksel O., Kuday C. Persistent nonmigrated ventral primitive ophthalmic artery. Report on one case. Journal of Neuroradiology. 1994;21(1):46–49.spa
dc.relation.references33. Hannequin P., Peltier J., Destrieux C., Velut S., Havet E., Le Gars D. The inter-optic course of a unique precommunicating anterior cerebral artery with aberrant origin of an ophthalmic artery: an anatomic case report. Surgical and Radiologic Anatomy. 2013;35(3):269–271. doi: 10.1007/s00276-012-10286spa
dc.relation.references34. Li Y., Horiuchi T., Yako T., Ishizaka S., Hongo K. Anomalous origin of the ophthalmic artery from the anterior cerebral artery. Neurologia MedicoChirurgica. 2011;51(8):579–5spa
dc.relation.references35. Huynh-Le P., Natori Y., Sasaki T. Surgical anatomy of the ophthalmic artery: Its origin and proximal course. Neurosurgery. 2005;57(supplement 4):236– 241. Hayreh S. S. Orbital vascular anatomy. Eye. 2006;20(10):1130–1144.spa
dc.relation.references36. Manjandavida, F. P., Stathopoulos, C., Zhang, J., Honavar, S. G., & Shields, C. L. (2019). Intra-arterial chemotherapy in retinoblastoma - A paradigm change. Indian journal of ophthalmology, 67(6), 740–7spa
dc.relation.references37. Gobin, Y.P., et al., Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 129(6): p. 732-7.spa
dc.relation.references38. Shields, C.L., et al., Intra-arterial Chemotherapy for Retinoblastoma: Report No. 2, Treatment Complications. Arch Ophthalmol. 129(11): p. 1407-15spa
dc.relation.references39. Abramson, D.H., Chemosurgery for retinoblastoma: what we know after 5 years. Arch Ophthalmol. 129(11): p. 1492-4. Shields, C.L., et al., Intra-arterial Chemotherapy for Retinoblastoma: Report No. 2, Treatment Complications. Arch Ophthalmol. 129(11): p. 1407-15spa
dc.relation.references40. Abramson, D.H., Chemosurgery for retinoblastoma: what we know after 5 years. Arch Ophthalmol. 129(11): p. 1492-4spa
dc.relation.references41. Brodie, S.E., et al., Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma. Doc Ophthalmol, 2009. 119(1): p. 13-22spa
dc.relation.references42. Munier, F.L., et al., Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina. 2011; 31(3): p. 566-7spa
dc.relation.references43. Vijayakrishnan, R., et al., Irradiation toxic effects during intra-arterial chemotherapy for retinoblastoma: should we be concerned? Arch Ophthalmol. 128(11): p. 1427-31spa
dc.relation.references44. Suzuki, S., et al., Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 118(10): p. 2081-7spa
dc.relation.references45. Peterson EC, Elhammady MS, Quintero-Wolfe S, Murray TG, Aziz-Sultan MA. Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: Initial experience with 17 tumors. J Neurosurg 2011;114:1603-8spa
dc.relation.references46. Muen WJ, Kingston JE, Robertson F, Brew S, Sagoo MS, Reddy MA. Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma. Ophthalmology 2012;119:611-6.spa
dc.relation.references47. Thampi S, Hetts SW, Cooke DL, Stewart PJ, Robbins E, Banerjee A, et al. Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: Results from a single institution. Clin Ophthalmol 2013;7:981-9spa
dc.relation.references48. Venturi C, Bracco S, Cerase A, Cioni S, Galluzzi P, Gennari P, et al. Superselective ophthalmic artery infusion of melphalan for intraocular retinoblastoma: Preliminary results from 140 treatments. Acta Ophthalmol 2013;91:335-42spa
dc.relation.references49. Shields CL, Manjandavida FP, Lally SE, Pieretti G, Arepalli SA, Caywood EH, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: Outcomes based on the international classification of retinoblastoma. Ophthalmology 2014;121:1453-6spa
dc.relation.references50. Taich P, Ceciliano A, Buitrago E, Sampor C, Fandino A, Villasante F, et al. Clinical pharmacokinetics of intra-arterial melphalan and topotecan combination in patients with retinoblastoma. Ophthalmology 2014;121:88997spa
dc.relation.references51. Parareda A, Català J, Carcaboso AM, Sola T, Cruz O, Díaz J, et al. Intraarterial chemotherapy for retinoblastoma. Challenges of a prospective study. Acta Ophthalmol 2014;92:209-15spa
dc.relation.references52. Ghassemi F, Ghanaati H, Karkhaneh R, Boujabadi L, Tabatabaie SZ, Rajabi MT. Outcome of retinoblastoma following limited sessions of intra-arterial chemotherapy in Iran. Iran J Radiol 2014;11:e16958spa
dc.relation.references53. Ong SJ, Chao AN, Wong HF, Liou KL, Kao LY. Selective ophthalmic arterial injection of melphalan for intraocular retinoblastoma: A 4-year review. Jpn J Ophthalmol 2015;59:109-17spa
dc.relation.references54. Akyüz C, Kıratlı H, Şen H, Aydın B, Tarlan B, Varan A. Intra-arterial chemotherapy for retinoblastoma: A single-center experience. Ophthalmologica 2015;234:227-32spa
dc.relation.references55. Abramson DH, Marr BP, Francis JH, Dunkel IJ, Fabius AW, Brodie SE, et al. Simultaneous bilateral ophthalmic artery chemosurgery for bilateral retinoblastoma (tandem therapy). PLoS One 2016;11:e0156806.spa
dc.relation.references56. Tuncer S, Sencer S, Kebudi R, Tanyıldız B, Cebeci Z, Aydın K. Superselective intra-arterial chemotherapy in the primary management of advanced intra-ocular retinoblastoma:First 4-year experience from a single institution in Turkey. Acta Ophthalmol 2016;94:e644-51.spa
dc.relation.references57. Michaels ST, Abruzzo TA, Augsburger JJ, Corrêa ZM, Lane A, Geller JI. Selective ophthalmic artery infusion chemotherapy for advanced intraocular retinoblastoma: CCHMC early experience. J Pediatr Hematol Oncol 2016;38:65-9spa
dc.relation.references58. Leal-Leal CA, Asencio-López L, Higuera-Calleja J, Bernal-Moreno M, BoschCanto V, Chávez-Pacheco J, et al. Globe salvage with intra arterial topotecan-melphalan chemotherapy in children with a single eye. Rev Invest Clin 2016;68:137-42spa
dc.relation.references59. Reddy MA, Naeem Z, Duncan C, Robertson F, Herod J, Rennie A, et al. Reduction of severe visual loss and complications following intra-arterial chemotherapy (IAC) for refractory retinoblastoma. Br J Ophthalmol 2017;101:1704-8spa
dc.relation.references60. Chen M, Jiang H, Zhang J, Shen G, Jiang Y, Li H, Liu Z. Outcome of intraarterial chemotherapy for retinoblastoma and its influencing factors: A retrospective study. Acta Ophthalmol 2017;95:613-8spa
dc.relation.references61. Rishi P, Sharma T, Sharma M, Maitray A, Dhami A, Aggarwal V, et al. Intraarterial chemotherapy for retinoblastoma: Two-year results from tertiary eyecare center in India. Indian J Ophthalmol 2017;65:311-5spa
dc.relation.references62. Ammanuel S, Alexander MD, Damato B, Cooke DL, Halbach VV, Amans MR, et al. Improved procedural safety following protocol changes for selective ophthalmic arterial infusion of chemotherapy for treatment of ocular retinoblastoma. Interv Neuroradiol 2018;24:345-50.spa
dc.relation.references63. Hua J, Gang S, Yizhou J, Jing Z. Intra-arterial chemotherapy as second-line treatment for advanced retinoblastoma: A 2-year single-center study in China. J Cancer Res Ther 2018;14:106-110spa
dc.relation.references64. Radros J, All-Eriksson C, Pal N, Holm S, Seregard S, Söderman M, et al. Intra-arterial chemotherapy for retinoblastoma in Sweden – Evaluation of treatment efficacy and complications. Acta Ophthalmol 2018;96:e1040-1spa
dc.relation.references65. Rojanaporn D, Chanthanaphak E, Boonyaopas R, Sujirakul T, Hongeng S, Ayudhaya SSN. Intra-arterial chemotherapy for retinoblastoma: 8-year experience from a tertiary referral institute in Thailand. Asia Pac J Ophthalmol (Phila) 2019. doi: 10.22608/APO.2018294.spa
dc.relation.references66. Instituto Nacional De Cancerologia de Colombia. Anuario Estad.stico. 2010:18spa
dc.relation.references67. CL Shields, EM Fulco, JD Arias. Retinoblastoma frontiers with intravenous, intraarterial, periocular, and intravitreal chemotherapy. Eye (2012), 1–12.spa
dc.relation.references68. www.salud.gob.sv › boletines epidemiológicos 2019spa
dc.relation.references69. Global Retinoblastoma Study Group, Fabian ID, Abdallah E, et al. Global Retinoblastoma Presentation and Analysis by National Income Level [published online ahead of print, 2020 Feb 27]. JAMA Oncol. 2020;6(5):1-12spa
dc.relation.references70. Bravo LE, García LS, Collazos P, Carrascal E, Ramírez O, Cortés A, Nuñez M, Millán E . I. Reliable data for cancer control in Cali, Colombia. Colomb Med (Cali). 2018; 49(1): 23-34.spa
dc.relation.references71. Abramson DH, Fabius AWM, Issa R, Francis JH, Marr BP, Dunkel IJ, et al. (2015) Advanced Unilateral Retinoblastoma: The Impact of Ophthalmic Artery Chemosurgery on Enucleation Rate and Patient Survival at MSKCC. PLoS ONE 10(12): e0145436spa
dc.relation.references72. Area C, Yen CJ, Chevez-Barrios P, Herzog C, Kan P, Zheng W, Lin F, Chintagumpala M, Gombos D, Chen SR. Technical and anatomical factors affecting intra-arterial chemotherapy fluoroscopy time and radiation dose for intraocular retinoblastoma. J Neurointerv Surg. 2019 Dec;11(12):1273-1276spa
dc.relation.references73. Shields CL, Shields JA. Editorial: chemotherapy for retinoblastoma. Med Pediatr Oncol. Jun 2002;38(6):377-378spa
dc.relation.references74. Harbour JW. What is the best treatment for retinoblastoma? Am J Ophthalmol. Sep 2004;138(3):471-473.Chantada GL, Fandino AC, Raslawski 76 EC, et al. Experience with chemoreduction and focal therapy for intraocular retinoblastoma in a developing country. Pediatr Blood Cancer. 2005;44(5):455-460.spa
dc.relation.references75. Shields CL, De Potter P, Himelstein BP, Shields JA, Meadows AT, Maris JM. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114(11):1330-1338.spa
dc.relation.references76. Shields JA, Shields CL, Meadows AT. Chemoreduction in the management of retinoblastoma. Am JOphthalmol. 2005;140(3):505-50spa
dc.relation.references77. Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial Chemotherapy for Retinoblastoma: Report No. 2, Treatment Complications. Arch Ophthalmol. 2011spa
dc.relation.references78. Abramson DH. Chemosurgery for retinoblastoma: what we know after 5 years. Arch Ophthalmol.2011;129(11):1492-1494spa
dc.relation.references79. Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011;129(6):732-737spa
dc.relation.references80. Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH. Intra-arterial Chemotherapy for the Management of Retinoblastoma: Four-Year Experience. Arch Ophthalmol. 20spa
dc.relation.references81. Abramson DH, Shields CL, Munier FL, Chantada GL. Treatment of Retinoblastoma in 2015:Agreement and Disagreement. JAMA Ophthalmol. 2015;133(11):1341-13spa
dc.relation.references82. Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial Chemotherapy for Retinoblastoma:Report No.1, Control of Retinal Tumors, Subretinal Seeds, and Vitreous Seeds. Arch Ophthalmol.2spa
dc.relation.references83. Reese AB, Hyman GA, Merriam GR, Jr., Forrest AW, Kligerman MM. Treatment of retinoblastoma by radiation and triethylenemelamine. AMA Arch Ophthalmol. 1954;53(4):505-513.spa
dc.relation.references84. Kaneko A, Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn JClin Oncol. 2003;33(12):601-607spa
dc.relation.references85. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients With intraocular retinoblastoma. Int J Clin Oncol. 2004;9(2):69-73spa
dc.relation.references86. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial(ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results.Ophthalmology. 2008;115(8):13981404, 1404 e1391spa
dc.relation.references87. Shields CL, Manjandavida FP, Lally SE, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014;121(7):1453–60.spa
dc.relation.references88. Marr BP, Brodie SE, Dunkel IJ, Gobin YP, Abramson DH. Threedrug intraarterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results. Br J Ophthalmol. 2012;96(10):1300–3.spa
dc.relation.references89. Buitrago E, Del Sole MJ, Torbidoni A, et al. Ocular and systemic toxicity of intravitreal topotecan inrabbits for potential treatment of retinoblastoma. Exp Eye Res. 2013;108:103-109.spa
dc.relation.references90. Bogan CM, Kaczmarek JV, Pierce JM, et al. Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study. Br J Ophthalmol. 2021spa
dc.relation.references91. Ghassemi F, Shields CL. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 2012;130(10):12681271spa
dc.relation.references92. .Shields CL, Kaliki S, Rojanaporn D, Al-Dahmash S, Bianciotto CG, Shields JA. Intravenous and intraarterial chemotherapy for retinoblastoma: what have we learned? Curr Opin Ophthalmol. 2012;23(3):202209.spa
dc.relation.references93. Dalvin, L. A., Kumari, M., Essuman, V. A., Shohelly Shipa, S., AnconaLezama, D., Lucio-Alvarez, J. A., Jabbour, P., & Shields, C. L. (2019). Primary Intra-Arterial Chemotherapy for Retinoblastoma in the Intravitreal Chemotherapy Era: Five Years of Experience. Ocular oncology and pathology, 5(2), 139–146.spa
dc.relation.references94. González M.E, López M, Enucleation Free Survival of Patients with Retinoblastoma Diagnosis Treated with Intraarterial Chemotherapy at University-Based San Vicente Fundacion Hospital.Rev. Sociedad Colombiana de Oftalmología Vol. 47 (2): 161 - 169, 2014spa
dc.relation.references95. Ravindran K, Dalvin LA, Pulido JS, Brinjikji W. Intra-arterialchemotherapy for retinoblastoma: An updated systematicreview and meta-analysis. J Neurointerv Surg.2019;11:1266–72,http://dx.doi.org/10.1136/neurintsurg2019-014909.2spa
dc.relation.references96. Yousef YA, Soliman SE, Astudillo PPP, Durairaj P, Dimaras H,Chan HSL, et al. Intra-arterial chemotherapy forretinoblastoma: A systematic review. JAMA Ophthalmol.2016;134:58491spa
dc.relation.references97. González ME, Gaviria ML, López M, Escudero PA, Bravo A, Vargas SA. Eye Salvage with Intra-Arterial and Intra-Vitreal Chemotherapy in Patients with Retinoblastoma: 8-Year Single-Institution Experience in Colombia. Ocul Oncol Pathol. 2021 Jun;7(3):215-223. doi: 10.1159/000511980spa
dc.relation.references98. Rojanaporn D, Chanthanaphak E, Boonyaopas R, Sujirakul T,Hongeng S, Ayudhaya SSN. Intra-arterial chemotherapy forretinoblastoma: 8-year experience from a tertiary referralinstitute in Thailand. Asia Pac J Ophthalmol (Phila).2019;8:211–7.spa
dc.relation.references99. Funes S, Sampor C, Villasante F, Fandi–o A, Manzitti J, Sgroi M, Neira P, Peralta L, Lagomarsino E, Schaiquevich P, Ceciliano A, Chantada GL. Feasibility and results of an intraarterial chemotherapy program for the conservative treatment of retinoblastoma in Argentina. Pediatr Blood Cancer. 2018 Aug;65(8):e27086. doi: 10.1002/pbc.27086spa
dc.relation.references100. Ting, S. C., Kiefer, T., Ehlert, K., Goericke, S. L., Hinze, R., Ketteler, P., Bechrakis, N. E., & Schildhaus, H. U. (2020). Bone metastasis of retinoblastoma five years after primary treatment. American journal of ophthalmology case reports, 19, 100834spa
dc.relation.references101. Roncallo Kelsey LG, Detection of Extraocular Lesions in A Patient with Bilateral Retinoblastoma Using 18F-FDG PET/CT.Biomedical Journal of Scientific & Technical Research April, 2019, Volume 17, 2, pp 12632-12634spa
dc.relation.references102. Kaewkhaw, R. y Rojanaporn, D. (2020). Retinoblastoma: etiología, modelado y tratamiento. Cánceres , 12 (8), 2304. https://doi.org/10.3390/cancers1208spa
dc.contributor.cvlacMantilla García, Daniel Eduardo [0001437130]spa
dc.contributor.cvlacOchoa Vera, Miguel Enrique [0000898465]spa
dc.contributor.googlescholarMantilla García, Daniel Eduardo [PUqdPK8AAAAJ]spa
dc.contributor.orcidOchoa Vera, Miguel Enrique [0000-0002-4552-3388]spa
dc.contributor.scopusMantilla García, Daniel Eduardo [6641574500]spa
dc.contributor.scopusOchoa Vera, Miguel Enrique [36987156500]spa
dc.contributor.researchgateOchoa Vera, Miguel Enrique [Miguel-Ochoa-6]spa
dc.subject.lembCiencias médicasspa
dc.subject.lembRadiologíaspa
dc.subject.lembDiagnóstico para imágenesspa
dc.subject.lembFarmacologíaspa
dc.subject.lembNeoplasmas de los ojosspa
dc.subject.lembEnfermedades de los ojosspa
dc.identifier.repourlrepourl:https://repository.unab.edu.cospa
dc.description.abstractenglishObjective: To evaluate the efficacy and safety of treatment with intra-arterial chemotherapy through the ophthalmic artery in patients with retinoblastoma in FOSCAL- FOSCAL INTERNACIONAL in the period between 2013-2020. Justification: Intra-arterial chemotherapy changed the treatment strategy for retinoblastoma, it provides a high success rate for salvage of the eyeball and for tumor control. In order to expand knowledge about the feasibility of this sophisticated procedure in a middle-income country like ours, we want to present our experience in patients from northeastern Colombia with intraocular retinoblastoma managed with supraselective intra-arterial chemotherapy. Type of study: This is a descriptive cohort study based on secondary data. Population: All eligible patients diagnosed with retinoblastoma from January 1, 2013 to September 1, 2020 undergoing selective intra-arterial chemotherapy through the ophthalmic artery in FOSCAL- FOSCAL INTERNATIONAL will be included, it will be a census study. Results: When evaluating the total number of eyes for the 10 children affected by retinoblastoma, it was 65% (13/20 eyes), of which 11 were treated with chemoembolization. Stage categorization was performed according to the international classification of retinoblastoma, observing that of the 11 eyes taken to QIA, 63.64% (n=7) were category D, followed by category E 27.27% (n=3) and category C 9.09% (n=1). When evaluating overall survival, no patient died and the median follow-up was 53 months. The mean enucleation-free survival was 23 months, the first enucleation of the 11 eyes after chemoembolization was at 6 months. Conclusions: Intra-arterial chemotherapy is a powerful, safe, and effective modality that can reduce the rate of enucleation in patients with retinoblastoma. Better response was observed in group C; however, it would be ideal to define the risk/benefit of such treatment for a larger number of patients in early stages. Group E patients all ended up in enucleation, which reinforces the findings of the different studies in which the efficacy in advanced stages is low and enucleation is preferre.spa
dc.subject.proposalCiencias de la saludspa
dc.subject.proposalQuimioterapia intraarterialspa
dc.subject.proposalRetinoblastomaspa
dc.subject.proposalArteria oftálmicaspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TM
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.coverage.campusUNAB Campus Bucaramangaspa
dc.description.learningmodalityModalidad Presencialspa


Ficheros en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 2.5 Colombia
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 2.5 Colombia